MOTS-c vs SS-31: Two Mitochondrial Peptides Compared

Published September 2026 · Patriot Labs Research Team · ~15 min read

The short answer

MOTS-c is a 16-amino-acid peptide that the mitochondria’s own DNA encodes and that acts as a metabolic signal; SS-31 is a synthetic four-amino-acid peptide, also called elamipretide, that binds a lipid in the inner mitochondrial membrane and stabilizes its structure. They share a mitochondrial theme, but one is a naturally encoded messenger and the other is an engineered structural compound with a very different chemistry, research history and regulatory status.

The clearest way to hold the two apart is by what they do to a mitochondrion. MOTS-c behaves like information: it is produced from the mitochondrial genome, engages the cellular energy sensor AMPK, and under stress even travels to the cell nucleus to influence which genes are switched on.^[1][2] SS-31 behaves like a repair strut: it concentrates in the inner mitochondrial membrane, binds the phospholipid cardiolipin, and helps keep the folded membrane surfaces (the cristae) and the electron-transport machinery intact.^[3][4]

Everything else in this guide follows from that split — a signaling peptide versus a membrane-targeted structural peptide — including why they turn up in different research fields and why only one of them is, as of 2025, an approved medicine. The rest of the article takes each difference in turn.

At a glance: the core differences

The two peptides differ on almost every axis that matters: their size, their origin, where they act, how they act, and how far each has travelled through clinical development. The table below summarizes the contrasts covered in detail in the rest of the guide.

What MOTS-c is

MOTS-c is a mitochondrial-derived peptide: a short chain of 16 amino acids whose instructions sit inside the mitochondria’s own small genome rather than in the cell’s nuclear DNA. It was described in 2015 by Lee and colleagues, who reported that the peptide is encoded within the mitochondrial 12S ribosomal RNA region and that it promotes metabolic balance in laboratory models.^[1]

The name is an abbreviation of “mitochondrial open reading frame of the twelve-S rRNA type-c,” which is really a description of where its coding sequence lives. That location is the single most distinctive thing about it: most peptides in a catalogue are fragments or analogues of molecules encoded by nuclear genes, whereas MOTS-c is one of a small family of peptides that the mitochondrion writes itself. Because mitochondria are the cell’s energy compartments, a peptide encoded there and acting on energy metabolism is of natural interest to researchers studying how cells sense and manage fuel. The single-compound background is covered in What Is MOTS-c?, and its place among longevity-adjacent compounds in Best Peptides for Anti-Aging & Longevity Research.

In research settings MOTS-c is frequently described as an “exercise-mimetic,” a term that means it engages some of the same cellular signaling that physical activity does. That is a mechanistic label used in the laboratory, not a statement about any outcome; the exercise connection is examined more closely in the mechanism and research sections below.

What SS-31 is

SS-31 is a synthetic tetrapeptide — four amino acids — engineered specifically to reach the interior of the mitochondrion and act on its membranes. It emerged from a series of “Szeto-Schiller” (SS) peptides first reported by Zhao, Szeto and colleagues in 2004 as cell-permeable, mitochondria-targeted peptide antioxidants.^[6] The “SS” is for the two researchers; the “31” is the compound number in that series.

Unlike MOTS-c, SS-31 is not something the body makes. Its published sequence is D-Arg-Dmt-Lys-Phe-NH₂ — a chain built from a D-form arginine, the non-standard residue 2′,6′-dimethyltyrosine (Dmt), lysine and a phenylalanine capped as an amide.^[5] Those are deliberate, non-natural choices: the alternating positively charged and aromatic residues are what let the peptide cross membranes and concentrate where it is meant to work, and the D-amino acid and terminal amide make it far more resistant to the enzymes that would ordinarily chew up a short peptide.

SS-31 is also the compound the pharmaceutical industry knows as elamipretide. It has been developed clinically by Stealth BioTherapeutics and studied across several mitochondrial-linked conditions; in 2025 it became an approved drug for one of them.^[8] The single-compound explainer is What Is SS-31?, and the naming question is returned to in the regulatory section.

Origin: encoded by DNA vs designed in a lab

The deepest difference between the two is where they come from. MOTS-c is a naturally encoded peptide; SS-31 is a from-scratch chemical design. That single distinction explains most of the others.

MOTS-c is transcribed and translated from a sequence inside the mitochondrial genome, the 12S rRNA region, and is present in human tissue and blood.^[1] When a research supplier sells MOTS-c, the material is made by chemical synthesis, but the sequence being copied is one the body already uses. That makes MOTS-c a “natural” peptide in the sense that its sequence occurs in nature, even though the vial’s contents were manufactured — the same situation as many hormone peptides, discussed in Recombinant vs Synthetic Peptides and What Are Peptides?

SS-31 has no natural counterpart. It was assembled residue by residue to satisfy a design brief: get into the mitochondrion regardless of the membrane voltage, and bind a specific lipid once there. Its use of a D-amino acid and of dimethyltyrosine — building blocks the ribosome does not use — places it firmly in the category of engineered peptides. The general question of natural versus synthetic origin, and why a manufactured peptide can still carry a natural sequence, is covered in Where Are Peptides Made? The practical upshot for this comparison is simple: MOTS-c reproduces a message biology already sends, while SS-31 introduces a molecule biology never made.

Mechanism: a signal vs a structural stabilizer

MOTS-c and SS-31 act on mitochondria in fundamentally different modes: MOTS-c works as a signal that changes cellular behavior, while SS-31 works as a structural agent that binds a membrane component directly. Neither description below is a claim about any effect in a person; each summarizes how the compound is understood to act in laboratory research.

How MOTS-c is understood to work

In the research literature, MOTS-c is studied as an activator of AMP-activated protein kinase (AMPK), the enzyme cells use as a low-fuel sensor. The proposed route is indirect: MOTS-c interferes with the folate cycle and one-carbon metabolism, which alters levels of an intermediate (AICAR) that in turn engages AMPK.^[1] A second, striking feature was reported by Kim and colleagues in 2018: under metabolic stress, MOTS-c moves out of the mitochondria and into the cell nucleus, where it interacts with stress-responsive gene programs, including antioxidant-response pathways, and changes which nuclear genes are expressed.^[2] In other words, a peptide made in one organelle ends up regulating the genome in another — behaving like a messenger between the two.

How SS-31 is understood to work

SS-31’s mechanism is physical rather than signaling. It concentrates in the inner mitochondrial membrane and binds cardiolipin, a distinctive phospholipid found almost exclusively there.^[3][4] Cardiolipin helps organize the tightly folded cristae and holds respiratory-chain complexes and cytochrome c in working order. By binding cardiolipin, SS-31 is reported to stabilize cristae structure, support the assembly and stability of respiratory complexes I, III and IV, and reduce the electron leakage that generates reactive oxygen species.^[5] Szeto’s work also describes SS-31 preventing cardiolipin from turning cytochrome c into a damaging peroxidase while preserving its normal role as an electron carrier.^[3][4] The recurring theme is protection of existing machinery, not activation of a signaling cascade.

So the two operate on different levels entirely. MOTS-c changes what the cell does — its metabolic program — from the level of gene expression and enzyme signaling. SS-31 changes the physical state of a membrane and the machinery embedded in it. It is the difference between sending an instruction and reinforcing a structure.

Structure and chemistry

The size and building blocks of the two peptides could hardly be more different: MOTS-c is a mid-length peptide of ordinary amino acids, while SS-31 is a very short chain built partly from non-natural residues. Those choices drive their stability and their behavior in the lab.

Two design points on the SS-31 side are worth drawing out because they explain its behavior. First, the alternating aromatic-cationic pattern is what lets a positively charged peptide slip across membranes at all: the review by Tung and colleagues describes the positive charge being “shielded” by the electrons in the aromatic rings, so the peptide can cross despite its charged residues, then accumulate where cardiolipin is densest.^[5] Second, the non-natural residues are a stability strategy — a general theme covered in Peptide Half-Life Extension, which explains how D-amino acids, terminal amides and similar edits slow enzymatic breakdown. MOTS-c, being an ordinary L-peptide, does not carry those modifications and is handled by the body as a normal peptide substrate. How peptides in general are assembled and purified is covered in How Peptides Are Made.

Where each one appears in research

Because their mechanisms differ, the two peptides show up in largely separate research literatures: MOTS-c in metabolism, exercise and aging; SS-31 in mitochondrial disease and organ bioenergetics. Knowing which field a compound lives in is often the fastest way to tell them apart.

MOTS-c: metabolism, exercise and aging

The original 2015 report framed MOTS-c around metabolic homeostasis in laboratory models.^[1] The most cited follow-up is the 2021 study by Reynolds and colleagues in Nature Communications, which described MOTS-c as an exercise-induced, mitochondrially encoded regulator of age-related physical decline in mice, and reported that exercise raises circulating MOTS-c in human skeletal muscle and blood.^[7] That work is the origin of the “exercise-mimetic” framing and of MOTS-c’s recurring appearance in longevity discussions. Its levels are also reported to decline with age, which is part of why it spans both metabolic and aging research. Importantly, the human evidence is observational or preclinical: no large randomized controlled trials of administered MOTS-c in people have been published.^[7]

SS-31: mitochondrial disease and organ bioenergetics

SS-31/elamipretide has been carried much further into formal clinical testing, across conditions united by mitochondrial dysfunction. The 2025 review by Tung and colleagues catalogues the major trials: TAZPOWER in Barth syndrome, MMPOWER-3 in primary mitochondrial myopathy, ReCLAIM in dry age-related macular degeneration, and PROGRESS-HF in heart failure.^[5] The results have been mixed rather than uniformly positive — the review notes, for example, that the heart-failure study did not meet its primary endpoint — which is itself a useful reminder that reaching clinical trials is not the same as demonstrating benefit across every setting.^[5] The through-line is bioenergetics: wherever failing mitochondrial membranes are implicated, SS-31 has been a candidate to study.

Regulatory status: an approved drug vs a research compound

This is where the two peptides diverge most sharply for anyone handling them. SS-31 has become an approved medicine in one specific form and indication, while MOTS-c has no approved drug at all — and neither fact changes what a research-grade vial is.

On 19 September 2025, the US Food and Drug Administration granted accelerated approval to elamipretide — the clinical name for SS-31 — under the brand name Forzinity, as the first treatment for Barth syndrome, a rare inherited mitochondrial disease.^[8] The FDA described the drug as working by binding the inner part of the mitochondria to improve mitochondrial structure and function, and based the accelerated approval on an improvement in knee muscle strength considered reasonably likely to predict benefit, with a confirmatory trial required afterward.^[8] The approval is narrow: a specific manufactured product, for a specific rare disease, in a defined patient group.

MOTS-c has no comparable status. There is no FDA-approved MOTS-c product, and, as noted above, no large randomized controlled trials of administered MOTS-c in humans have been published.^[7]

The essential point for research use cuts across both. A research compound that shares a name with an approved drug is not that drug: it has not been manufactured under the approved product’s regulated, inspected quality system, it has not been through that product’s release testing, and it is not sold for the same purpose. Research-grade SS-31 is not Forzinity, just as research-grade material of any kind is not the medicine that may share its sequence. The distinction between research-grade and pharmaceutical-grade material is set out in Peptide vs Drug vs Biologic, and what independent testing can and cannot show is covered in Understanding Peptide COA Testing. For this comparison, treat elamipretide’s approval as a fact about a pharmaceutical product and a milestone in the compound’s history — not as a property of a research vial.

Are they studied together?

MOTS-c and SS-31 are often discussed together because both concern the mitochondrion, but they act on different parts of it, and in the research literature they are treated as complementary rather than interchangeable. This section describes how the two are positioned in research; it is not a protocol and does not describe combining anything for use.

The conceptual reason they are paired is that they address mitochondrial biology from opposite directions. SS-31 targets the physical integrity of the inner membrane and its respiratory machinery; MOTS-c operates at the level of metabolic signaling and gene expression.^[2][4] One is structural, one is regulatory. That non-overlap is exactly why writers group them: together they sketch two different research strategies for thinking about mitochondrial function — keep the hardware intact, and change the instructions the cell acts on.

What the literature does not provide is any established human regimen involving either peptide, let alone the two in combination. Both remain, for the purposes of a research catalogue, laboratory compounds; MOTS-c has no approved human use, and SS-31’s single approval is a specific drug product for a specific rare disease. Anyone comparing them for study design should treat them as two distinct tools with distinct mechanisms, and should rely on primary sources rather than on the convenience of a shared “mitochondrial peptide” label. Related mechanism-level reading includes What Is MOTS-c? and What Is SS-31? for the single-compound detail.

Sourcing, testing and quality

For research material, the questions that matter are the same for both peptides and have nothing to do with which mechanism is more interesting: is the vial what the label says, and is that claim backed by lot-specific documentation? Identity and purity are established the same way for a 4-residue peptide as for a 16-residue one — by analytical testing, not by branding.

Two techniques carry most of the weight. High-performance liquid chromatography (HPLC) measures purity: it separates the target peptide from truncated chains, deletion sequences and other process-related impurities and reports the target as a percentage of the whole. Mass spectrometry establishes identity: it measures the molecular mass and confirms it matches the intended sequence — a check that is especially worth having for SS-31, whose non-natural residues (D-Arg, Dmt) and C-terminal amide give it a specific mass that ordinary substitutions would not reproduce. A certificate of analysis (COA) that names the lot, the methods and the testing laboratory ties those results to the physical material in hand; Understanding Peptide COA Testing explains how to read one, and Peptide Purity Grades Explained covers what a purity percentage does and does not mean.

For reference: Patriot Labs is a first-responder-owned, US-based company, and every batch it sells is tested by an independent US laboratory by HPLC and mass spectrometry, with the certificate of analysis published on the product page. Those are the same documents this section recommends asking any vendor for, whichever compound is in the vial. The product pages for these two peptides are MOTS-c and SS-31.

What this comparison does not establish

This guide compares two research compounds as objects of study. It does not establish anything about their use in people or animals, and several of its points come with limits worth stating plainly.

• Nothing here describes use in a person or animal. Mechanisms are described as they are studied in the laboratory; none of it is guidance for use, and no dose, route or regimen is given for either peptide.
• Mechanisms are models, not settled fact. The AMPK/folate route for MOTS-c and the cardiolipin-binding account of SS-31 are the leading published explanations, but mechanistic understanding evolves as new work appears.
• Clinical results are mixed and mostly narrow. Elamipretide’s approval is for one rare disease on an accelerated basis with a confirmatory trial pending, and several of its other trials did not meet their primary endpoints. MOTS-c has no large human trials at all.^[5][7][8]
• An approved drug is not the research compound. Elamipretide (Forzinity) is a specific pharmaceutical product; research-grade SS-31 is not that product, and this guide makes no claim that they are equivalent in quality or in anything else.
• “Better” is not a meaningful question here. The two peptides do different things by different means; which is more relevant depends entirely on the research question, not on any ranking.

Frequently asked questions

What is the difference between MOTS-c and SS-31?

MOTS-c and SS-31 are both studied in the context of mitochondria, but they are different kinds of molecule. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S ribosomal RNA gene and studied as a metabolic signaling molecule that activates the energy sensor AMPK. SS-31 is a synthetic four-amino-acid peptide, also known as elamipretide, designed to bind cardiolipin in the inner mitochondrial membrane and stabilize its structure. One is a naturally encoded signal; the other is an engineered structural compound.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the research designation for the peptide developed clinically as elamipretide. In September 2025 the US FDA granted accelerated approval to elamipretide (brand name Forzinity) as the first treatment for Barth syndrome. A research compound labeled SS-31 and sold for laboratory use is not the approved medicine and is not intended for human use.

Is MOTS-c a natural peptide?

MOTS-c is encoded within the mitochondria’s own DNA, specifically the 12S ribosomal RNA gene, and is produced in the body, so in that sense it is naturally occurring. The material sold for research is manufactured by chemical synthesis to match that sequence. SS-31, by contrast, contains non-natural building blocks and does not occur in nature.

Are MOTS-c and SS-31 studied for the same things?

Not exactly. MOTS-c is studied mostly in metabolic, exercise and longevity research, where it acts as a signaling peptide. SS-31 (elamipretide) is studied mostly in mitochondrial-disease and bioenergetics research, including Barth syndrome, primary mitochondrial myopathy, heart failure and eye disease, where it acts on mitochondrial membrane structure. Their mechanisms are different, which is why they appear in different bodies of literature.

Is MOTS-c FDA approved?

No. There is no FDA-approved MOTS-c drug, and no large randomized controlled trials of exogenous MOTS-c in humans have been published. SS-31, as elamipretide, holds one accelerated FDA approval for the rare condition Barth syndrome; that approval applies to the specific pharmaceutical product, not to research-grade material that shares the name.

References

1. Lee, C., Zeng, J., Drew, B. G., Sallam, T., et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 21(3), 443–454. doi:10.1016/j.cmet.2015.02.009
2. Kim, K. H., Son, J. M., Benayoun, B. A., & Lee, C. (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism, 28(3), 516–524. doi:10.1016/j.cmet.2018.06.008
3. Szeto, H. H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029–2050. doi:10.1111/bph.12461
4. Birk, A. V., Chao, W. M., Bracken, C., Warren, J. D., & Szeto, H. H. (2014). Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology, 171(8), 2017–2028. doi:10.1111/bph.12468
5. Tung, and colleagues. (2025). Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences, 26(3), 944. doi:10.3390/ijms26030944
6. Zhao, K., Zhao, G. M., Wu, D., Soong, Y., et al. (2004). Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane Inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury. Journal of Biological Chemistry, 279(33), 34682–34690. doi:10.1074/jbc.M402999200
7. Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12, 470. doi:10.1038/s41467-020-20790-0
8. U.S. Food and Drug Administration (19 September 2025). FDA Grants Accelerated Approval to First Treatment for Barth Syndrome (elamipretide / Forzinity, Stealth BioTherapeutics). https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome

For more on the compounds and concepts this guide touches, see What Is MOTS-c? and What Is SS-31? for the single-compound explainers, Best Peptides for Anti-Aging & Longevity Research for the research area MOTS-c sits in, Peptide Half-Life Extension for why SS-31’s non-natural residues matter, and Understanding Peptide COA Testing for how identity and purity are verified.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and compares two compounds in general scientific terms; it is not medical advice, does not describe how to use any product, and makes no claim about outcomes in humans or animals. A research compound that shares a name with an approved drug is not that drug.